Dr. Guerard’s career in the pharmaceutical industry spans over 25 years and includes multiple leadership, strategic and commercial roles. Dr. Guerard served as the Chief Executive Officer of Graybug Vision, Inc., a clinical‐stage pharmaceutical company developing potentially transformative therapies for ocular diseases. He led the clinical development of a late‐stage wet AMD product candidate. Dr. Guerard led the merger of Graybug with CalciMedica, Inc. and remains a non‐executive Board member of CalciMedica. Dr. Guerard acted as the Worldwide Business Franchise Head of Ophthalmology at Novartis. In this role, he successfully led the integration of Novartis Retina and Alcon Pharmaceuticals and accelerated the rejuvenation of the product pipeline through strategic acquisitions and licensing transactions in dry eye disease, presbyopia, and inherited retinal diseases. Prior to this role, he served as Global Franchise Head of Pharmaceuticals at Alcon. Dr. Guerard held additional leadership positions at Novartis, including Head of UK, Ireland, North and West Africa, Head and Country President of Australia, New Zealand and Egypt and Head of Marketing and Sales for Emerging Growth Markets. Dr. Guerard holds a PharmD and a Master of Biological and Medical Sciences from the University of Rouen, and a Master of Marketing from HEC Paris, France.